QCG
ARQT icon

Quadrant Capital Group’s Arcutis Biotherapeutics ARQT Stock Holding History

Quadrant Capital Group’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$36.5K Hold
1,550
– – ﹤0.01% 1802
2025
Q4 		$45K Hold
1,550
– – ﹤0.01% 1724
2025
Q3 		$29.2K Buy
+1,550
New +$24.4K ﹤0.01% 1830
2025
Q2 		– Sell
-1,550
Closed -$24.2K – 1418
2025
Q1 		$24.2K Hold
1,550
– – ﹤0.01% 1982
2024
Q4 		$21.6K Hold
1,550
– – ﹤0.01% 1856
2024
Q3 		$14.4K Hold
1,550
– – ﹤0.01% 2029
2024
Q2 		$14.4K Sell
1,550
-326
-17% -$2.95K ﹤0.01% 1988
2024
Q1 		$18.6K Buy
+1,876
New +$14K ﹤0.01% 1878
2023
Q4 		– Sell
-936
Closed -$4.97K – 2698
2023
Q3 		$4.97K Buy
936
+875
+1,434% +$7.44K ﹤0.01% 2177
2023
Q2 		$582 Buy
+61
New +$677 ﹤0.01% 2554

Other funds holding ARQT

SCM
Suvretta Capital Management New York $3.69B AUM 86.67% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $8.16B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $22.9B AUM 115.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return